Search - tctmd.com

Displaying 1 - 20 of 47

Sort: Relevancy | Date

News Industry News

NIH - Sponsored Trial of Pharmaco-mechanical Thrombolysis with the BASHIRTM Endovascular Catheter Demonstrates Unprecedented Reduction in Pulmonary Artery Obstruction in Patients with Acute Pulmonary Embolism

September 16, 2022

News Industry News

Boston Scientific Initiates Randomized Controlled Trial for the EkoSonic™ Endovascular System

August 04, 2021

News Industry News

Medtronic Venous Stent Recieves U.S. FDA Approval to Treat Venous Outflow Obstruction

October 26, 2020

News Industry News

Thrombolex Bashir® Endovascular Catheter First-In-Human (FIH) Trial for Acute Pulmonary Embolism Confirms Early Safety and Feasibility and Impressive Reduction of Clot Burden

March 05, 2020

News Industry News

Thrombolex, Inc. Announces First Patient Enrolled in Early Feasibility & Safety Study Using the Bashir™ Endovascular Catheter for Pulmonary Embolism

July 29, 2019

News Industry News

Boston Scientific Initiates Trial Comparing Left Atrial Appendage Closure to Direct Oral Anticoagulants for Stroke Risk Reduction Post-AFib Ablation

May 22, 2019

News Industry News

Thrombolex, Inc. Announces 510(K) Premarket Notification Clearance Of The Bashir™ Endovascular Catheter And The Bashir N-X™ Endovascular Catheter For The Treatment Of Acute Venous And Arterial Thromboembolic Disorders

May 13, 2019

News Industry News

New Real-World Analysis Finds Lower Risk of Major Bleeding and Similar Risk of Stroke with Standard Dose of Pradaxa® Compared to Rivaroxaban in NVAF Patients Newly Initiating Treatment

January 29, 2018

News Industry News

Voluntary Recall of Fetch™ 2 Aspiration Catheter

April 11, 2016

News Industry News

Voluntary Recall of Chariot™ Guiding Sheath

December 09, 2015

News Industry News

Boston Scientific Receives FDA Approval And CE Mark For AngioJet™ ZelanteDVT™ Thrombectomy Catheter

November 30, 2015

News Industry News

Boston Scientific Receives CE Mark For Next Generation WATCHMAN FLX™ Left Atrial Appendage Closure Device

November 19, 2015

News Industry News

FDA approves Praxbind, the first reversal agent for the anticoagulant Pradaxa

October 20, 2015

News Industry News

Bristol-Myers Squibb and Pfizer Enroll First Patient in Phase 4 AUGUSTUS Trial to Evaluate Safety of Eliquis (apixaban) in Nonvalvular Atrial Fibrillation Patients with a Recent ACS or Undrgoing PCI

September 09, 2015

News Industry News

Acute Pulmonary Embolism Trial (SEATTLE II) Published in the JACC: Cardiovascular Interventions

August 24, 2015

News Industry News

First U.S. Patients Enroll in Boehringer Ingelheim's Global RE-DUAL PCI™ and RE-CIRCUIT™ Trials Evaluating Pradaxa® (dabigatran etexilate mesylate)

July 29, 2015

News Industry News

NICE recommends once-daily LIXIANA® (edoxaban) for the treatment and prevention of recurrent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in adults

July 13, 2015

News Industry News

Daiichi Sankyo gets EU OK for Lixiana anticoagulant

June 26, 2015

News Industry News

Idarucizumab Reverses the Anticoagulant Effect of Dabigatran Within Minutes in Patient Study

June 22, 2015

News Industry News

One-Year Outcomes Data on Stroke Prevention in Patients With Newly Diagnosed Atrial Fibrillation (AF) to Be Presented at ISTH 2015

June 18, 2015

Advertisement

NIH - Sponsored Trial of Pharmaco-mechanical Thrombolysis with the BASHIRTM Endovascular Catheter Demonstrates Unprecedented Reduction in Pulmonary Artery Obstruction in Patients with Acute Pulmonary Embolism

Boston Scientific Initiates Randomized Controlled Trial for the EkoSonic™ Endovascular System

Medtronic Venous Stent Recieves U.S. FDA Approval to Treat Venous Outflow Obstruction

Thrombolex Bashir® Endovascular Catheter First-In-Human (FIH) Trial for Acute Pulmonary Embolism Confirms Early Safety and Feasibility and Impressive Reduction of Clot Burden

Thrombolex, Inc. Announces First Patient Enrolled in Early Feasibility & Safety Study Using the Bashir™ Endovascular Catheter for Pulmonary Embolism

Boston Scientific Initiates Trial Comparing Left Atrial Appendage Closure to Direct Oral Anticoagulants for Stroke Risk Reduction Post-AFib Ablation

Thrombolex, Inc. Announces 510(K) Premarket Notification Clearance Of The Bashir™ Endovascular Catheter And The Bashir N-X™ Endovascular Catheter For The Treatment Of Acute Venous And Arterial Thromboembolic Disorders

New Real-World Analysis Finds Lower Risk of Major Bleeding and Similar Risk of Stroke with Standard Dose of Pradaxa® Compared to Rivaroxaban in NVAF Patients Newly Initiating Treatment

Voluntary Recall of Fetch™ 2 Aspiration Catheter

Voluntary Recall of Chariot™ Guiding Sheath

Boston Scientific Receives FDA Approval And CE Mark For AngioJet™ ZelanteDVT™ Thrombectomy Catheter

Boston Scientific Receives CE Mark For Next Generation WATCHMAN FLX™ Left Atrial Appendage Closure Device

FDA approves Praxbind, the first reversal agent for the anticoagulant Pradaxa

Bristol-Myers Squibb and Pfizer Enroll First Patient in Phase 4 AUGUSTUS Trial to Evaluate Safety of Eliquis (apixaban) in Nonvalvular Atrial Fibrillation Patients with a Recent ACS or Undrgoing PCI

Acute Pulmonary Embolism Trial (SEATTLE II) Published in the JACC: Cardiovascular Interventions

First U.S. Patients Enroll in Boehringer Ingelheim's Global RE-DUAL PCI™ and RE-CIRCUIT™ Trials Evaluating Pradaxa® (dabigatran etexilate mesylate)

NICE recommends once-daily LIXIANA® (edoxaban) for the treatment and prevention of recurrent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in adults

Daiichi Sankyo gets EU OK for Lixiana anticoagulant

Idarucizumab Reverses the Anticoagulant Effect of Dabigatran Within Minutes in Patient Study

One-Year Outcomes Data on Stroke Prevention in Patients With Newly Diagnosed Atrial Fibrillation (AF) to Be Presented at ISTH 2015

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content